AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 12th, 2015 • Zafgen, Inc. • Pharmaceutical preparations
This Amendment No. 4 to Exclusive License Agreement (this “Amendment”) is entered into as October 29, 2014, by and between Zafgen, Inc., a Delaware corporation (“Zafgen”), and Chong Kun Dang Pharmaceutical Corporation, a corporation organized under the laws of the Republic of Korea (“CKD”), and amends that certain Exclusive License Agreement, dated as of July 6, 2009, by and between Zafgen and CKD, as amended to date (the “Agreement”). Defined terms used but not otherwise defined herein, shall have the meanings ascribed to such terms in the Agreement.
SUBSCRIPTION AGREEMENTSubscription Agreement • January 12th, 2015 • Zafgen, Inc. • Pharmaceutical preparations • Massachusetts
THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of November 20, 2014 (the “Effective Date”), by and between Zafgen, Inc., a Delaware corporation (“Zafgen”), and Chong Kun Dang Pharmaceutical Corporation, a corporation organized under the laws of the Republic of Korea (“CKD”). Zafgen and CKD are referred to herein as the “Parties,” or each, a “Party.” Capitalized terms used, but not defined herein shall have the meanings ascribed to such terms in the License Agreement (as defined below).
